Agencies agree to purchase investigational antiviral if authorized by FDA
The departments of Health and Human Services and Defense will purchase 1.7 million treatment courses of an investigational antiviral drug for $1.2 billion if the Food and Drug Administration approves or authorizes the therapy, the Biden administration announced today.
If authorized, the federal government will allocate the drug (molnupiravir) to states and territories. Health care providers would order the drug directly from the distributor within those allocations, HHS said.
Related News Articles
Headline
The U.S. District Court for the District of Massachusetts yesterday ruled in favor of 25 states and the District of Columbia to vacate the Centers for Medicare…
Headline
The AHA Oct. 27 submitted comments on the Supporting Underserved and Strengthening Transparency, Accountability, and Integrity Now and for the Future of 340B…
Headline
The AHA Oct. 20 expressed support for the Addressing Boarding and Crowding in the Emergency Department (ABC-ED) Act (S. 1974), bipartisan legislation designed…
Headline
AHA leaders this week are participating in the International Hospital Federation’s 2026 World Hospital Congress in Seoul, South Korea. On Oct. 20, Bill Gassen,…
Headline
The AHA provided recommendations to the Food and Drug Administration Oct. 19 on potential regulatory frameworks for generative artificial intelligence-enabled…
Headline
An executive order issued by the White House Oct. 19 directs the Department of Health and Human Services, through the National Institutes of Health, to…